"Piperazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D010879
|
| MeSH Number(s) |
D03.383.606
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperazines".
Below are MeSH descriptors whose meaning is more specific than "Piperazines".
This graph shows the total number of publications written about "Piperazines" by people in this website by year, and whether "Piperazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 4 | 1 | 5 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 3 | 3 |
| 2002 | 1 | 1 | 2 |
| 2003 | 2 | 0 | 2 |
| 2004 | 5 | 1 | 6 |
| 2005 | 1 | 1 | 2 |
| 2006 | 7 | 1 | 8 |
| 2007 | 3 | 5 | 8 |
| 2008 | 10 | 2 | 12 |
| 2009 | 3 | 2 | 5 |
| 2010 | 4 | 3 | 7 |
| 2011 | 3 | 3 | 6 |
| 2012 | 2 | 2 | 4 |
| 2013 | 8 | 4 | 12 |
| 2014 | 5 | 4 | 9 |
| 2015 | 8 | 3 | 11 |
| 2016 | 1 | 2 | 3 |
| 2017 | 5 | 4 | 9 |
| 2018 | 2 | 7 | 9 |
| 2019 | 4 | 2 | 6 |
| 2020 | 1 | 7 | 8 |
| 2021 | 5 | 6 | 11 |
| 2022 | 1 | 4 | 5 |
| 2023 | 1 | 2 | 3 |
| 2024 | 4 | 4 | 8 |
| 2025 | 3 | 4 | 7 |
| 2026 | 4 | 5 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Piperazines" by people in Profiles.
-
Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia (SILDI-SAFE): A Randomized Controlled Trial. J Pediatr. 2026 Aug; 295:115147.
-
Emerging Dolutegravir Resistance Among Children on Antiretroviral Therapy With Virological Failure in Malawi: Results From a 2023 National Cross-Sectional Survey. J Int AIDS Soc. 2026 May; 29(5):e70108.
-
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials. Lancet Oncol. 2026 May; 27(5):592-603.
-
Dolutegravir developmental toxicity is mitigated by magnesium and folate in zebrafish embryos. Dis Model Mech. 2026 May 01; 19(5).
-
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial. Lancet HIV. 2026 Jun; 13(6):e367-e379.
-
Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer. Cancer Res. 2026 Apr 02; 86(7):1707-1723.
-
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer. ESMO Open. 2026 Apr; 11(4):106063.
-
Tolerability of lopinavir versus dolutegravir in children and adolescents with HIV. AIDS. 2026 May 01; 40(5):600-610.
-
Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance. Pediatr Infect Dis J. 2026 Jul 01; 45(7):620-622.
-
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors. Sci Transl Med. 2025 Aug 27; 17(813):eadq5492.